- Home
- KAVL vs SILO Comparison
KAVL vs SILO Comparison
Compare KAVL & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KAVL | SILO |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KAVL | SILO |
|---|---|---|
| Price | $0.13 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 120.2K |
| Earning Date | 02-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,127,037.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.12 | $0.36 |
| 52 Week High | $1.55 | $3.37 |
Technical Indicators
Market Signals| Indicator | KAVL | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 22.62 | 40.32 |
| Support Level | $0.14 | $0.37 |
| Resistance Level | $0.23 | $0.43 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 5.16 | 15.90 |
Price Performance
Historical ComparisonAbout KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.